Attendee search 

Aderly Invest in Lyon is the economic development agency of Lyon - France

Our software enables a rapid development of web or mobile portals or "app stores", dedicated to help people to manage their health or autonomy.

Technically, we facilitate interaction between services, serious games, algorithms and medical contents that will be integrated in a single portal where they will have a single management tool and one single database.

In addition, an administration tool enables to its operator the management of the platform : CMS, enrollment, statistics and connectors.

To date, we expect 1 M€ turnover in 2015, with 6 customers, mainly insurers and state organization like CNAM, the equivalent of NHS, the Regional Health Agency (ARS Ile de France) or City of Paris.

For instance, we have developed an e-health portal for employees. This portal, called "MyPrevention", integrates 12 inter-connected applications : e-health prevention applications, an encyclopedia, information and coaching platforms, ...

The services are provided by 12 different companies.

About this project, our lauching plan, forecasts 50 000 users by the end of October 2015 and 400.000 in 2016.

We have also developped a social network which integrates a serious game, an agenda, a visio conference access, a connection with a services platform.

This project has been designed for the dependant persons of the city of Paris and will be launched and operated by the Welfare Department of the City of Paris.

Even if the French market is still under creation, we strongly believe that market shares must be grabbed now. So far, we have a successful commercial activity and we are strongly confident that we will be in a strong position to address a mass e-health market. 

This market will be driven by the demand expressed by end users who expect more collaboration between insurers, national healthcare operators , pharmaceutical labs,  in order to provide them with integrated care services.

Our strategy is always the same :

- identifying the main actors on a market

- finalizing partnership in order to adress the market behind his brand and his expertise.

Our companion software embed patient-doctor connectivity and clinical intelligence into existing therapeutics or medical devices. We rely on our ISO-certified processes, medical algorithms and clinical studies of our software to create solutions that ensure safety and efficacy for our users.

People suffering from chronic diseases often find themselves lost in their treatment protocols once they leave the doctor's office. They lack a way of communicating with their health care teams and the support to take the appropriate dose of medication, manage symptoms and control side effects.

Pharmaceutical companies / Health care payers / Medical device manufacturers

Convergence of medical and technological solutions / Results backed by clinical trials / Quality and regulatory expertise / Extensive track record

Backed by unique experience acquired through more than 600 clients, including the world

At the core of our innovative connection-based concept, our qualifying approach generates as much information as possible about the pharmacological behavior of a molecule. With this approach, Oncodesign aims to optimally position each molecule towards a disease indication and a patient population, in order to maximize its value.

Pharmaceutical Labs / Biotechs / Academics

Innovation: Oncodesign devises new solutions (Pharmimage)

• Indigo designs, manufactures and supplies innovative dietary supplements focused on gastrointestinal tract (GIT) pathologies and conditions or deficiencies requiring specific clinical nutrition
• Gynov, Indigo's sister company, applies the same rules of design and manufacturing for gynecological / obstetrics sphere

• Gastroenterology / Hepatology
• Immunology
• Infectious Diseases - Vaccines
• Nutrition and Weight Loss
• Obstetrics/Gynecology (Women's Health)

Besides opportunistic developments, our R&D aims at producing new generation probiotics / synbiotics combining a selection of relevant strains in relation to the progresses on microbiota, a microencapsulation technology promoting the survival and the production of molecules of interest, and a pharmaceutical macro-encapsulation vectorizing active ingredients to the therapeutic target

Indigo addresses medical problems or conditions which currently lack of efficient or well-tolerated solutions. Besides, Indigo provides a clear rational while exploiting the potential of probiotics / synbiotics still faces some uncertainty among healthcare professionals.

Gynov addresses obstetrical issues for which currently available medications are contra-indicated. Thus, Gynov conceives specialized dietary supplements based upon high-quality GRAS ingredients that have demonstrated their efficacy for Gyn/Obst issues

• Irritable bowel disease (IBD)
• Prevention & treatment of diarrheas
• Dialysis for end-stage renal failure
• Fertility & obstetrics

• Robust medico-scientific background
• High manufacturing & product quality (GMP)
• Exclusive promotion towards medical doctors
• High value academic partnerships

OsseoMatrix has developed a direct 3D printing process of biological ceramics which enables the manufacturing of patient specific synthetic bone implants

The bioceramic implants developed by OsseoMatrix fit the anatomical complexity of cranio-maxillo-facial or orthopaedic bone losses, resulting of trauma, infection, tumor.

Market 1: Cranio-facial Market 2: Dental Market 3 Orthopaedic 4 Laboratories

advantage 1 less invasive / advantage 2 same composition as bone / advantage 3 patient specific / advantage 4 regenerative

1) Developement of patented injectable resorbable biomaterials which harden in situ, allowing minimally invasive surgery and are quickly resorbed by the cellular activity and replaced by natural bone. 2) Design and development of combinaison devices utilizing synthetic bone substitute materials and therapeutic agents as well as autologous tissue which will address such clinical challenges as prevention of osteoporotic fractures, prevention of infection and enhanced bone ingrowth

1) Bone defect filling via MIS techniques for younger patients; 2) "Super-Fast" resorption and remodeling to boost bone reconstruction for non union management; 3) Local treatment or prevention of osteoporotic patient ; 4) management of bone Infection by our innovative calcium phosphate cement combined with antibiotic (exposed trauma, military application...)

1) Orthopaedic: Trauma and Reconstruction; 2) Spine Surgery; 3)Dentistry

1) Patented technology which provides unique soluctions to address key clinical needs; 2) Proprietary pipeline of innovative bone tissue engineering solutions; 3) Fully integrated organization and facilities which include R&D, manufacturing, regulatory, sales and marketing; 4) Strong relationships with leading global orthopedic companies; 5) years of very successful sales and clinical experience in 23 countries of the world

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

• CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
• Curie Cancer, a component of Institut Curie focused on cancers
• ICM, the Brain and Spine Institute dedicated to CNS diseases
• Pasteur MI, the infectious diseases division of the Institut Pasteur
• Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Basic research / Preclinical research / Clinical

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

ProtecSom designs smart respiratory drug delivery devices to improve pulmonary drug distribution and patients life.

Optim'Hal provides real-time information on the drug dose inhaled from a metered dose inhaler with a spacer device. It sends this information to any computer, smartphone or tablet and also converts it as light and sound signals to encourage drug taking among toddlers.

Compliance is a major problem with asthma sufferers. Thanks to incentive provided to patients, children and parents, Optim'Hal improves compliance. The inhaled dose and speed of the inspiratory flow are critical to the reliability of the inhaled treatment. Thanks to information about these settings, Optim'Hal' makes the treatment more reliable.

Asthma and COPD sufferers. /Any inhaled treatment. /Research centers about aerosoltherapy.

Better compliance, thanks to incentive signals or applications depending on the age / Better surveillance, thanks to true data on patient compliance available for caregivers / Improving pulmonary drug distribution thanks to information on inspiratory flow